# Nuclide record full-life-technologies (company). Data CC BY-NC 4.0, attribute "Data from Nuclide (nuclide.cc)". Whole corpus: https://nuclide.cc/api/v1/nuclide.nt
@prefix schema: <https://schema.org/> .
@prefix nuclide: <https://nuclide.cc/ns#> .
@prefix xsd: <http://www.w3.org/2001/XMLSchema#> .

<https://nuclide.cc/companies/full-life-technologies/>
  a schema:Organization ;
  nuclide:kind "company" ;
  schema:identifier "full-life-technologies" ;
  schema:name "Full-Life Technologies"@en ;
  schema:alternateName "Full-Life"@en ;
  schema:description "A radiopharmaceutical drug developer with sites in Europe and China that designs its own targeting molecules and pairs them with radioactive actinium or lutetium; its biggest programme, for a receptor found on several solid tumour types, has been licensed to a Korean partner in a deal worth up to $571.5 million."@en ;
  schema:url <https://nuclide.cc/companies/full-life-technologies/>, <https://www.full-life.com> ;
  schema:dateModified "2026-09-22"^^xsd:date ;
  schema:citation <https://www.full-life.com/media/press-releases/28>, <https://www.full-life.com/media/press-releases/42>, <https://www.fiercebiotech.com/biotech/sk-inks-572m-deal-full-life-prospect-advancing-push-become-asias-radiopharma-leader>, <https://www.full-life.com/media/press-releases/26>, <https://wewillcure.com/insights/company-profiles/oncology/biotech-companies-advancing-radiopharmaceutical-treatments> ;
  nuclide:status "active" ;
  nuclide:tag "actinium-225", "neurotensin receptor 1", "radionuclide drug conjugate" ;
  schema:addressCountry "DE" ;
  nuclide:related <https://nuclide.cc/targets/psma/>, <https://nuclide.cc/indications/prostate-mcrpc/>, <https://nuclide.cc/technologies/targeted-alpha-therapy/>, <https://nuclide.cc/isotopes/lu-177/>, <https://nuclide.cc/isotopes/ac-225/> .